Low prevalence of nonconservative mutations of serum and glucocorticoid-regulated kinase (SGK1) gene in hypertensive and renal patients

被引:11
|
作者
Trochen, N
Ganapathipillai, S
Ferrari, P
Frey, BM
Frey, FJ
机构
[1] Univ Hosp, Div Nephrol & Hypertens, Bern, Switzerland
[2] Univ Western Australia, Fremantle Hosp, Dept Nephrol, Perth, WA 6009, Australia
关键词
end-stage renal disease; genetics; glucocorticoids; hypertension; SGK1;
D O I
10.1093/ndt/gfh417
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. The serum- and glucocorticoid-regulated kinase (SGK1) gene is an important mediator of aldosterone action, regulating the expression of the renal epithelial Na+ channel. In renal failure, blood pressure (BP) is markedly salt-dependent and increases with decreasing renal function. Mutations of the SGK1 gene affecting phosphorylation could be responsible for salt-mediated increases in BP and hypertension-related progression to end-stage renal disease (ESRD). Methods. The SGK1 gene was analysed for mutations in the exons 4, 5, 8 and 10-12, because of potential phosphorylation sites, in 591 subjects, including 311 ESRD patients (either dialysis or transplanted). In addition, an intron 6 single-nucleotide polymorphism (SNP) described previously was also investigated in this study. Genotyping was performed either by using a strategy based on single strand conformation polymorphism analysis of polymerase chain reaction (PCR) products and subsequent direct sequencing of identified gel shift variants or by using high throughput 5' nuclease allelic discrimination assay. Results. Two SNPs in coding regions of SGK1 potentially influencing the phosphorylation of Sgk1 were identified. Both SNPs were synonymous. The prevalence of the first variant, a previously reported SNP at codon 240 in exon 8, did not differ between ESRD patients (16.3%) and controls (15.7%). There was no association between the SNP in exon 8 and either BP within the control population or progression of renal disease in the ESRD population. The second SNP at codon 398 in exon 12 was identified in one patient only. Intron 6 and exon 8 SNPs were in strong linkage disequilibrium, but did not show any association with either BP or renal diseases. Conclusions. Based on statistical analysis homozygosity for nonconservative mutations in the coding region of the SGK1 gene is estimated at <1/300 000 when a white Caucasian population is considered, arguing against an important role of mutations of this coding region in hypertension and hypertension-associated progression of renal disease.
引用
收藏
页码:2499 / 2504
页数:6
相关论文
共 50 条
  • [1] Serum- and glucocorticoid-regulated kinase (SGK1) gene and blood pressure
    Busjahn, A
    Aydin, A
    Uhlmann, R
    Krasko, C
    Bähring, S
    Szelestei, T
    Feng, YX
    Dahm, S
    Sharma, AM
    Luft, FC
    Lang, F
    HYPERTENSION, 2002, 40 (03) : 256 - 260
  • [2] The Serum and Glucocorticoid-Regulated Kinase-1 (SGK1) in Hypoxic Renal Injury
    Rusai, K.
    Schmaderer, C.
    Strobl, M.
    Boini, K. M.
    Grenz, A.
    Kuhl, D.
    Heemann, U.
    Szabo, A. J.
    Lang, F.
    Lutz, J.
    PEDIATRIC NEPHROLOGY, 2010, 25 (09) : 1832 - 1832
  • [3] Role of Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) in Immune and Inflammatory Diseases
    Bian, Xixi
    Xue, Honglu
    Jing, Dehuai
    Wang, Yan
    Zhou, Guangxi
    Zhu, Fengqin
    INFLAMMATION, 2023, 46 (05) : 1612 - 1625
  • [4] Involvement of serum and glucocorticoid-regulated kinase 1 (SGK1) in term and preterm labor
    Chen, J. J.
    Zhang, D.
    Ruan, Y.
    HUMAN REPRODUCTION, 2019, 34 : 483 - 484
  • [5] Role of Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) in Immune and Inflammatory Diseases
    Xixi Bian
    Honglu Xue
    Dehuai Jing
    Yan Wang
    Guangxi Zhou
    Fengqin Zhu
    Inflammation, 2023, 46 : 1612 - 1625
  • [6] Serum and glucocorticoid-regulated kinase 1 (SGK1) as an emerging therapeutic target for cardiac diseases
    Yarmohammadi, Fatemeh
    Karimi, Gholamreza
    PHARMACOLOGICAL RESEARCH, 2024, 208
  • [7] Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors
    Hammond, Marlys
    Washburn, David G.
    Hoang, Tram H.
    Manns, Sharada
    Frazee, James S.
    Nakamura, Hiroko
    Patterson, Jaclyn R.
    Trizna, Walter
    Wu, Charlene
    Azzarano, Leonard M.
    Nagilla, Rakesh
    Nord, Melanie
    Trejo, Rebecca
    Head, Martha S.
    Zhao, Baoguang
    Smallwood, Angela M.
    Hightower, Kendra
    Laping, Nicholas J.
    Schnackenberg, Christine G.
    Thompson, Scott K.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (15) : 4441 - 4445
  • [8] Deletion of Serum and Glucocorticoid-regulated Kinase 1 (SGK1) in T Cells Attenuates Hypertension and Renal/Vascular Dysfunction
    Norlander, Allison E.
    Saleh, Mohamed A.
    Pandey, Arvind K.
    Itani, Hana A.
    Wu, Jing
    Xiao, Liang
    Dale, Bethany L.
    Harrison, David G.
    Madhur, Meena S.
    HYPERTENSION, 2016, 68
  • [9] Association of the serum and glucocorticoid regulated kinase (sgk1) gene with QT interval
    Busjahn, A
    Seebohm, G
    Maier, G
    Toliat, MR
    Nürnberg, P
    Aydin, A
    Luft, FC
    Lang, F
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2004, 14 (03) : 135 - 142
  • [10] Vascular Inflammation and Hypertension are Attenuated with T Cell Deletion of Serum and Glucocorticoid-regulated Kinase 1 (SGK1)
    Norlander, Allison E.
    Saleh, Mohamed A.
    Pandey, Arvind
    Itani, Hana A.
    Wu, Jing
    Dale, Bethany
    Harrison, David G.
    Madhur, Meena S.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36